FI93227B - Använding av en kolhydratförening in vitro för framställning eller isolering av viruspartiklar eller virusytpartiklar - Google Patents

Använding av en kolhydratförening in vitro för framställning eller isolering av viruspartiklar eller virusytpartiklar Download PDF

Info

Publication number
FI93227B
FI93227B FI863702A FI863702A FI93227B FI 93227 B FI93227 B FI 93227B FI 863702 A FI863702 A FI 863702A FI 863702 A FI863702 A FI 863702A FI 93227 B FI93227 B FI 93227B
Authority
FI
Finland
Prior art keywords
virus
binding
receptor
use according
viral
Prior art date
Application number
FI863702A
Other languages
English (en)
Finnish (fi)
Other versions
FI863702A (sv
FI863702A0 (sv
FI93227C (sv
Inventor
Karl-Anders Karlsson
Erling Norrby
Goeran Wadell
Original Assignee
Symbicom Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symbicom Ab filed Critical Symbicom Ab
Publication of FI863702A publication Critical patent/FI863702A/sv
Publication of FI863702A0 publication Critical patent/FI863702A0/sv
Publication of FI93227B publication Critical patent/FI93227B/sv
Application granted granted Critical
Publication of FI93227C publication Critical patent/FI93227C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18851—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (13)

1. Användning av en kolhydratförening in vitro för framställning eller isolering av viruspartiklar eller vi-5 rusytpartiklar, vilken kolhydratförening är vald ur grup-pen sfingosin-2-D-hydroxifettsyror med formeln O OH Il I
2. Användning enligt patentkravet 1, känne-t e c k n a d därav, att R är 25 GA1B, GlcB, GalBl-4GlcB, Galtzl—*4GalB, Galal-»3GalBl-4GlcB,
30 Galal->4GalBl->4GlcB, Fucal-»2GalBl-»4GlcB, GlcNAcBl-»3GalBl-»4GlcB, GalNAcBl->4GalBl-4GlcB, Galal-»3( Fucal-*2 )GalBl-*4GlcB,
35 GalBl->3GlcNAcBl->3GalBl->4GlcB, II 932 27 GalSl->4GlcNAc61-3Gaiei->4Glc3, GalSl-»3 (Fucal-»4 )GlcNAcfil-»3GalBl-»4Glce, eller GalBl-»4 (Fucal-»3 )GlcNAcBl-3GalBl->4GlcB.
3. Användning enligt patentkravet 1 eller 2, 5 kännetecknad därav, att föreningen föreligger i univalent form.
4. Användning enligt patentkravet 1 eller 2, kännetecknad därav, att föreningen föreligger i en sädan form, att däri förekommer flera bindningsstäl-
5. Användning enligt patentkravet 4, kännetecknad därav, att föreningen är multivalent kopp-lad tili en makromolekylbärare.
6. Användning enligt patentkravet 5, k ä n n e - 15 tecknad därav, att bäraren har en hydrofob yta, tili vilken en hydrofob del av föreningen är bunden genom hydrofobisk, icke-kovalent samverkan.
7. Användning enligt patentkravet 6, kännetecknad därav, att den hydrofoba ytan är en poly- 20 mer, säsom plast eller vilken som heist polymer, till vilken kopplats hydrofoba grupper.
8. Användning enligt patentkravet 4, kännetecknad därav, att föreningen är kovalent bunden tili makromolekylbäraren.
9. Användning enligt patentkravet 8, känne tecknad därav, att bäraren är en naturlig eller syntetisk polymer.
10. Användning enligt patentkravet 9, kännetecknad därav, att bäraren är en oligo- eller po- 30 lysackarid, en oligo- eller polypeptid, en kombination av dessa eller ett pä motsvarande sätt substituerat konju-gat.
10 Ien för viruset.
10 HN-C-CH-R--R. I 3 1 R0CHoCH I HO-CH-CH=CH-R3-R2 15 fytosfingosin-2-D-hydroxifettsyror med formeln
0 OH Il I
20 HN-C-CH-R„-R. I 3 1 R0CHoCH OH II 2I I H0-CH-CH-CH«-R„-Ro 25 z J z dihydrosfingosin-2-D-hydroxifettsyror med formeln
0 OH 30. ii I HN-C-CH-R--R. I 3 1 R0CH2CH III
35 HO-CH-CH2-CH2-R3-R2 varvid i formlerna I, II och III R är en monosackarid-grupp, som kan vara substituerad i 4-ställning med en mono-, di-, tri- eller tetrasackaridgrupp eller ett derivat 40 därav, R1 och R2 betecknar oberoende av varandra metyl eller gruppen en CHO, N02, NH2, OH, SH, CONHNH2, C0N3 eller COOH och R3 är en kolvätedel omfattande ett rakkedjat S 3 227 eller föregrenat, mättat eller omättat kolväte med en k-edjelängd av 5 - 30 kolatomer; D-galaktopyranosyl-B-di-glycerid; D-galaktopyranosyl-al-»6-D-galaktopyranosyl-B-diglycerid; 5 och kolhydratföreningar med formeln ^CH2-S02-R6-R4 ROCHXH IV \ CH2-S02-R6-R5 10 och roch2ch2so2r6r4 VII 15 där R betecknar som ovan, R4 och R5 betecknar oberoende av varandra metyl eller gruppen CHO, N02, NH2, OH, SH, C0NHNH2, C0N3 eller COOH och R6 är en kolvätedel omfattan-de ett rakkedjat eller förgrenat, mättat eller omättat kolväte med en kedjelängd av 5 - 30 kolatomer; och vilken 20 kolhydratförening förmär binda sig vid ett ställe pä ett virus, som igenkänner bindningsepitopen hos andra stegets virusbindande receptor.
11. Användning enligt nägot av patentkraven 5 -10, kännetecknad därav, att bäraren är poly-
35 L-lysin eller poly-D,L-alanin. 93227
12. Användning enligt nägot av patentkraven 1 -11, kännetecknat därav, att viruset hör tili familjen Adenoviridae, Herpetoviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Reoviridae, Picornaviri- 5 dae eller Retroviridae.
13. Användning enligt patentkravet 12, känne-t e c k n a d därav, att viruset är adenovirus, herpesvirus, influensa-virus, pässjuka-virus, Sendai-virus, rabiesvirus, rotavirus, reovirus och HTLV-virus. tl
FI863702A 1985-01-14 1986-09-12 Använding av en kolhydratförening in vitro för framställning eller isolering av viruspartiklar eller virusytpartiklar FI93227C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK17885 1985-01-14
DK17885A DK17885D0 (da) 1985-01-14 1985-01-14 Antiviralt middel
DK8600007 1986-01-13
PCT/DK1986/000007 WO1986003971A1 (en) 1985-01-14 1986-01-13 Antiviral agents

Publications (4)

Publication Number Publication Date
FI863702A FI863702A (sv) 1986-09-12
FI863702A0 FI863702A0 (sv) 1986-09-12
FI93227B true FI93227B (sv) 1994-11-30
FI93227C FI93227C (sv) 1995-03-10

Family

ID=8090653

Family Applications (1)

Application Number Title Priority Date Filing Date
FI863702A FI93227C (sv) 1985-01-14 1986-09-12 Använding av en kolhydratförening in vitro för framställning eller isolering av viruspartiklar eller virusytpartiklar

Country Status (11)

Country Link
US (2) US4859769A (sv)
EP (1) EP0207984B1 (sv)
JP (1) JPS62502260A (sv)
CN (1) CN86100608A (sv)
AU (1) AU580136B2 (sv)
DK (1) DK17885D0 (sv)
FI (1) FI93227C (sv)
IE (1) IE59036B1 (sv)
IL (1) IL77603A (sv)
NO (1) NO173298C (sv)
WO (1) WO1986003971A1 (sv)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534553A (en) * 1987-06-12 1996-07-09 Hoerrmann; Wilhelm Drug containing fatty amino alcohols or derivatives thereof
DE3819870A1 (de) * 1987-06-12 1988-12-29 Hoerrmann Wilhelm Arzneimittel auf der basis von fett-amino-alkoholen
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5344870A (en) * 1987-12-02 1994-09-06 Alberta Research Council Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
WO1989008499A1 (en) * 1988-03-17 1989-09-21 Nippon Fine Chemical Co., Ltd. Liposome
IT1235011B (it) * 1988-07-26 1992-06-16 Fidia Farmaceutici Sintesi di derivati di glicosfingolipidi ed in particolare di gangliosidi utilizzabili per la preparazione di immunoadsorbenti ed adsorbenti per affinita' impiegabili per la purificazione di anticorpi e di tossine specifiche, e per uso diagnostico
US5149782A (en) * 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
DE3840044A1 (de) * 1988-11-27 1990-06-07 Behringwerke Ag Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung
US6407072B1 (en) 1988-12-02 2002-06-18 Fidia S.P.A. Lysoganglioside derivatives
IT1235161B (it) * 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisogangliosidi
US5192551A (en) * 1989-05-02 1993-03-09 Johns Hopkins University Neutral glycolipid as an adsorbent for enteric viral pathogens
AU7153991A (en) * 1989-12-13 1991-07-18 Glycomed Incorporated Synthesis of rotavirus receptor saccharides
WO1991008747A1 (en) * 1989-12-13 1991-06-27 Glycomed Incorporated Synthetic receptor molecules recognizable by a rotavirus
US5466681A (en) * 1990-02-23 1995-11-14 Microcarb, Inc. Receptor conjugates for targeting penicillin antibiotics to bacteria
US6387884B1 (en) 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
US6391857B1 (en) 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
JP2911554B2 (ja) * 1990-06-25 1999-06-23 台糖株式会社 抗ウィルス剤
AU638146B2 (en) * 1990-06-27 1993-06-17 Dainippon Ink And Chemicals Inc. Alkylated oligosaccharides and acetyl derivatives of the same
CA2095642C (en) * 1990-08-02 1999-12-14 Howard C. Krivan Adhesion receptors for pathogenic or opportunistic microorganisms
US5843463A (en) * 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
EP0563256B1 (en) * 1990-12-21 1995-06-28 MicroCarb Inc. Use of host cell phospholipids for inhibiting bacterial colonization
US6121233A (en) * 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
JPH05279381A (ja) * 1991-09-13 1993-10-26 Dainippon Ink & Chem Inc 硫酸化オリゴ糖芳香族配糖体
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
TW261533B (sv) * 1992-07-16 1995-11-01 Kirin Brewery
WO1994009020A1 (en) * 1992-10-22 1994-04-28 Kirin Beer Kabushiki Kaisha Novel shingoglycolipid and use thereof
CA2153661A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5780441A (en) * 1993-04-15 1998-07-14 Kirin Beer Kabushiki Kaisha Sphingoglycolipid compounds and therapeutic uses thereof
EP0727216B1 (en) * 1994-07-15 2003-05-28 TAIYO KAGAKU Co., LTD. Medicinal composition containing sialic acid derivative
US5606512A (en) * 1994-07-27 1997-02-25 The Dow Chemical Company Determining the biodegradability of iminodiacetic acid derivatives
DE69515671T3 (de) * 1994-07-27 2004-06-17 The Dow Chemical Co., Midland Bestimmung der biodegradabilität von asparaginsäurederivaten, abbaubare chelatbildner, verwendungen und zusammensetzungen davon
US5730157A (en) * 1995-12-07 1998-03-24 Clarion Pharmaceuticals Inc. Method for treating viral infection
US5973128A (en) * 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
US6083921A (en) * 1998-01-12 2000-07-04 Xu; Kai Jian Pharmaceutical compositions and method of using same
ES2225084T3 (es) * 1999-02-23 2005-03-16 Takara Bio Inc. Fucogalactano sulfatado.
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
US6541013B1 (en) 2000-07-13 2003-04-01 Idaho Research Foundation, Inc. Methods and compositions for suppressing bovine leukemia virus with a Shiga toxin polypeptide
US7135173B2 (en) * 2000-07-13 2006-11-14 Idaho Research Foundation, Inc. Antiviral activity of Shiga toxin
FI20011403A (sv) * 2001-06-29 2002-12-30 Carbion Oy Förfarande och sammansättningar för behandling av magsjukdomar
EP1411952B1 (en) * 2001-06-29 2009-04-22 Glykos Finland Oy Use of at least one glycoinhibitor substance against infectious diseases
ES2324860T3 (es) * 2001-12-28 2009-08-18 Prysmian S.P.A. Cable de telecomunicaciones resistente al agua.
US7060685B2 (en) 2002-05-16 2006-06-13 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
WO2004004636A2 (en) * 2002-07-03 2004-01-15 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
JPWO2004037272A1 (ja) * 2002-10-22 2006-02-23 独立行政法人科学技術振興機構 デング熱ウィルス感染阻害剤
AU2003288119B2 (en) * 2002-11-21 2009-08-20 Pevion Biotech Ltd. High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
DE602004011272T2 (de) * 2003-11-19 2008-12-24 Glycomimetics, Inc. Spezifischer antagonist sowohl für e- als auch p-selektine
EP1685145A2 (en) * 2003-11-19 2006-08-02 GlycoMimetics, Inc. Glycomimetic antagonists for both e- and p-selectins
US8137397B2 (en) * 2004-02-26 2012-03-20 Boston Scientific Scimed, Inc. Medical devices
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
WO2006127906A1 (en) * 2005-05-25 2006-11-30 Glycomimetics, Inc. Heterobifunctional compounds for selectin inhibition
CN101291946B (zh) * 2005-08-09 2011-06-29 糖模拟物有限公司 对来自假单胞菌的pa-il凝集素、pa-iil凝集素或其两者的糖模拟物抑制剂
LT2264043T (lt) 2005-09-02 2017-12-11 Glycomimetics, Inc. Heterobifunkciniai pan-selektino inhibitoriai
WO2007143052A1 (en) * 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
JP5298020B2 (ja) * 2006-10-12 2013-09-25 グリコミメティクス， インコーポレイテッド ヘキソースおよびｎ−アセチルヘキソサミンの糖模倣体置換
NZ598863A (en) * 2007-02-09 2013-11-29 Glycomimetics Inc Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
WO2009152245A1 (en) * 2008-06-13 2009-12-17 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
JP5726171B2 (ja) * 2009-05-01 2015-05-27 グリコミメティックス インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
AU2012358150B2 (en) 2011-12-22 2017-07-20 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
CN104837492B (zh) 2012-12-07 2018-04-27 糖模拟物有限公司 使用e-选择素拮抗剂动员造血细胞的化合物、组合物和方法
EP3227310B1 (en) 2014-12-03 2019-07-31 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US11045485B2 (en) 2016-01-22 2021-06-29 Glycomimetics, Inc. Glycomimetic inhibitors of PA-IL and PA-IIL lectins
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
EP3596096A1 (en) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
EP3717013A1 (en) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
EP3732186A1 (en) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
EP3761994A1 (en) 2018-03-05 2021-01-13 GlycoMimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
CN114920788B (zh) * 2022-05-30 2024-07-30 天津科技大学 人乳三糖半乳糖基乳糖的制备

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1910715A1 (de) * 1968-03-04 1969-10-09 Stanley Drug Products Inc Antimikrobielle Faktoren und deren Verwendung
US3622666A (en) * 1968-03-04 1971-11-23 Stanley Drug Products Inc Methods for treating bacterial infections with phrenosin
DE2322562C2 (de) * 1972-11-06 1984-03-29 Pharmacia AB, Uppsala Verfahren zur Bestimmung von Antigenen in einer Probe
US4056322A (en) * 1973-12-14 1977-11-01 Strategic Medical Research Corporation Preparation of ethers of monosaccharides
US4397844A (en) * 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
FR2478104B1 (fr) * 1980-03-17 1986-08-08 Merieux Inst Nouveaux derives de gangliosides, leur preparation et leur application
US4397959A (en) * 1980-11-05 1983-08-09 Research Corporation Forced precipitation method for preparing antigen/antibody particles
US4476119A (en) * 1981-08-04 1984-10-09 Fidia S.P.A. Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions
AU561067B2 (en) * 1982-03-22 1987-04-30 Biocarb Ab Anti-bacterial composition containing an oligosaccharide
US4678747A (en) * 1983-02-18 1987-07-07 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies for detection of an H (O) blood group antigen
SE8304007D0 (sv) * 1983-07-15 1983-07-15 Karlsson Karl Anders Forening och komposition for terapeutisk eller diagnostisk anvendning samt forfarande for terapeutisk behandling
IT1168205B (it) * 1983-07-21 1987-05-20 Wellcome Italia Derivato di monsialo ganglioside dotato di attivita' antibatterica, antifungina ed antitumorale, composizioni che lo contengono e procedimento per la loro preparazione
EP0146810A3 (de) * 1983-12-05 1987-05-13 Solco Basel AG Verfahren zur Herstellung von Sphingosinderivaten
US4695553A (en) * 1985-11-01 1987-09-22 Becton Dickinson And Co., Inc. Method for increasing agglutination of groups of cells to produce improved cell layer interface in centrifuged blood sample using antibodies

Also Published As

Publication number Publication date
IE860075L (en) 1986-07-14
AU5351386A (en) 1986-07-29
DK17885D0 (da) 1985-01-14
IE59036B1 (en) 1993-12-15
NO173298B (no) 1993-08-16
NO863646L (no) 1986-11-14
WO1986003971A1 (en) 1986-07-17
NO863646D0 (no) 1986-09-12
EP0207984B1 (en) 1991-07-03
US4859769A (en) 1989-08-22
AU580136B2 (en) 1989-01-05
NO173298C (no) 1993-11-24
JPS62502260A (ja) 1987-09-03
FI863702A (sv) 1986-09-12
US4980462A (en) 1990-12-25
FI863702A0 (sv) 1986-09-12
EP0207984A1 (en) 1987-01-14
CN86100608A (zh) 1987-02-18
IL77603A (en) 1994-12-29
FI93227C (sv) 1995-03-10

Similar Documents

Publication Publication Date Title
FI93227B (sv) Använding av en kolhydratförening in vitro för framställning eller isolering av viruspartiklar eller virusytpartiklar
Westberg et al. Human glomerular basement membrane. Preparation and composition
Gao et al. Glycan microarrays as chemical tools for identifying glycan recognition by immune proteins
Paul et al. The α-anomeric form of sialic acid is the minimal receptor determinant recognized by reovirus
US11730786B2 (en) High molecular weight polysaccharide that binds and inhibits virus
Chai et al. Neoglycolipid technology: deciphering information content of glycome
JPH01503464A (ja) インフルエンザウイルスの感染の診断及び予防のための合成ペプチド並びにそれらの使用
BR112013007946B1 (pt) Composições farmacêuticas e imunogênicas compreendendo polipeptídeos de hemaglutinina
Vaheri et al. Mitogenic effect by lipopolysaccharide and pokeweed lectin on density-inhibited chick embryo fibroblasts
Springer et al. Functional aspects and nature of the lipopolysaccharide-receptor of human erythrocytes
DE69027330T2 (de) Antivirales material
JP2010540488A (ja) 糖タンパク質及びグリコシル化細胞及びそれらの調製方法
Song et al. Structure of novel gangliosides, deaminated neuraminic acid (KDN) containing glycosphingolipids, isolated from rainbow trout ovarian fluid
EP0162825B1 (en) The use of a specific carcinom associated antigen (hapten), fucosylsialosylgangliotetraose (fuc-gm1) in diagnostic or therapeutic procedures related to human lung cancer (small cell carcinomas)
Via et al. Effects of sodium butyrate on the membrane glycoconjugates of murine sarcoma virus-transformed rat cells.
EP0386140A1 (en) Factors associated with essential hypertension
US9260536B2 (en) Capture of pathogenic and non-pathogenic biopolymers and bioparticles
Kamishohara et al. Selective accumulation of the endoplasmic reticulum–Golgi intermediate compartment induced by the antitumor drug KRN5500
Shibata et al. Nephritogenic glycoprotein X: correlation between the purity of nephritogenic glycopeptide, nephritogenoside, and morphological manifestation of glomerulonephritis
Kanfer et al. Glycosphingolipids as receptors
ES2203636T3 (es) Agregados poteinicos acilados y su utilizacion con el fin de aumentar las señales en un ensayo inmunologico para la deteccion de anticuerpos.
MIZUOCHI Preparation of oligosaccharide probes (neoglycolipids) and their application to the elucidation of functions of the glycoprotein oligosaccharide chains
Harford et al. Chemical and physical properties of the hepatic receptor for asialoglycoproteins
Mahoney et al. Neoganglioproteins: probes for endogenous ganglioside receptors

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed
MM Patent lapsed

Owner name: SYMBICOM AKTIEBOLAG